Bayer's €2 Billion Hybrid Bond and the Missouri Ruling That Will Decide the Bill
Published on 09/24/2026 at 07:11 | Editorial boerse-global.de
Bayer has spent the past several months assembling a financing package that few European issuers could match in scale — and last Wednesday it added the final piece. After the close of trading, the Leverkusen-based agriculture and pharmaceuticals group placed €2 billion in hybrid bonds across two tranches, both with 30-year maturities. Demand ran hot: each tranche was multiple times oversubscribed.
The stock finished yesterday at €49.51, holding comfortably above its 50-day moving average of €48.42.
A financing chain built in stages
The hybrid issue caps a sequence of large-scale funding moves. Apollo, the financial investor, has already injected €3 billion of equity into a newly created subsidiary housing Bayer's contraception business. Conventional bond placements worth $5 billion have followed, alongside a $8 billion credit facility set up to backstop the glyphosate settlement and upcoming maturities — a line management intends to retire gradually through bonds and equity-like instruments.
Rating agencies treat the new hybrids as 50% equity, which is precisely the point. Bayer's total outstanding hybrid volume now stands at €6.55 billion, giving the credit watchers the cushion they want while sparing existing shareholders the dilution of a conventional rights issue. Management has ruled out such a capital increase for now.
Should investors sell immediately? Or is it worth buying Bayer?
The coupons are not cheap. The tranche carrying a six-year non-call period pays 5.75%, while the nine-year non-call tranche carries 6.25% — a lasting drag on the financial result and a constraint on future investment budgets.
Apollo's contribution to the debt picture
That Apollo transaction does more than add liquidity. It is expected to bring net financial debt down to €29–30 billion, against earlier management guidance of €32–33 billion. For a balance sheet weighed down by years of legacy liabilities, that is a meaningful step toward restoring strategic room to maneuver.
Portfolio pruning is running alongside. On Monday, Bayer agreed to sell the oncology drug Stivarga to Grünenthal for up to €375 million, with completion targeted for late 2026 or early 2027. Institutional money is taking notice: Amundi crossed the 3% voting rights threshold on September 14, disclosing a 3.04% stake.
The operating base and the pipeline
Bayer reaffirmed its full-year targets: adjusted EBITDA of €9.6–10.1 billion and core earnings per share of €4.30–4.90. The FDA has granted approval for Kerendia in chronic kidney disease associated with type 1 diabetes, adding a growth story to the drug pipeline. The shares are up 34% since the start of the year.
The $7.25 billion question in Missouri
Everything above, however, sits behind one unresolved legal fact. The collective glyphosate settlement of $7.25 billion — roughly €6.3 billion at the time it was struck in February — has only preliminary approval. Final judicial sign-off is still pending, and a hearing on that final approval was held at the Missouri Circuit Court on September 14. No ruling has been issued; a decision is expected at a later date.
Bayer at a turning point? This analysis reveals what investors need to know now.
Until that judgment becomes final, the $8 billion credit line remains a visible block on the balance sheet. Should the court reject the settlement structure or attach additional conditions, costs could spiral beyond calculation, the credit facility would have to be serviced under different terms, and Bayer would once again face unquantifiable individual claims. Rating agencies would likely tighten the screws, putting a conventional capital increase abruptly back on the table.
The reverse scenario is equally clear. If the settlement wins final approval, the single largest valuation risk of recent years is neutralized, and attention can return to operations — including efficiency programs such as shared specialized software with partners to speed up administrative processes.
What investors are actually watching
Two clocks are running at once: the court's timetable in Missouri and the completion schedule for the Apollo partnership and the Stivarga sale. Delays on either front would strain the deleveraging plan. As long as the shares stay above €48.42 and the portfolio disposals proceed as planned, the recovery narrative holds. The next decisive catalyst is the Missouri judge's ruling — the point at which Bayer either clears the path to a fundamental re-rating or confronts a fresh set of setbacks.
Ad
Bayer Stock: New Analysis - 24 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
